Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment
Current Oncology · 2024
DOI: 10.3390/curroncol31100474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Rachel Gravell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Radiosurgery, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Academic Clinical Fellowship, Cancer Research UK.
Abstract (Originalsprache)
Background
The study purpose was to develop a machine learning (ML)-based predictive model for event-free survival (EFS) in patients with hepatocellular carcinoma (HCC) undergoing stereotactic ablative radiotherapy (SABR).
Methods
Patients receiving SABR for HCC at a single institution, between 2017 and 2020, were included in the study. They were split into training and test (85%:15%) cohorts. Events of interest were HCC recurrence or death. Three ML models were trained, the features were selected, and the hyperparameters were tuned. The performance was measured using Harrell’s C index with the best-performing model being tested on the unseen cohort.
Results
Overall, 41 patients were included (training = 34, test = 7) and 64 lesions were analysed (training = 50, test = 14), resulting in 30 events (60% rate) in the training set (death = 6, recurrence = 24) and 8 events (57% rate) in the test set (death = 5, recurrence = 3). A Cox regression model, using age at treatment, albumin, and intra-lesional fat identified through MRI as variables, had the best performance with a mean training score of 0.78 (standard deviation (SD) 0.02), a mean validation of 0.78 (SD 0.18), and a test score of 0.94.
Conclusions
Predicting the outcomes in patients with HCC, following SABR, using a novel model is feasible and warrants further evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
- Leeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK.
- Department of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
ORCID-Profile: Russell Frood, Rebecca Goody, Andrew Scarsbrook
Förderung
- NIHR Academic Clinical Fellowship
- Cancer Research UK
Zitieren
APA
Gravell, R., Frood, R., Littlejohns, A., Casanova, N., Goody, R., Podesta, C., Albazaz, R., & Scarsbrook, A. (2024). Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment. Current Oncology. https://doi.org/10.3390/curroncol31100474
Vancouver
Gravell R, Frood R, Littlejohns A, Casanova N, Goody R, Podesta C, et al. Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment. Current Oncology. 2024. doi:10.3390/curroncol31100474
BibTeX
@article{Gravell2024,
author = {Gravell, Rachel and Frood, Russell and Littlejohns, Anna and Casanova, Nathalie and Goody, Rebecca and Podesta, Christine and Albazaz, Raneem and Scarsbrook, Andrew},
title = {Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31100474}
}
EUVIMED